



**MEDICARE ADVANTAGE  
PRIOR AUTHORIZATION REQUEST FORM**

Nuedexta - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Member Name:</b>	<b>Prescriber Name:</b>	
Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Line of Business: <input type="checkbox"/> Medicare Advantage	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	<b>Specialty/facility name (if applicable):</b>	

☐ **REQUEST FOR EXPEDITED REVIEW:** By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

**Please attach any pertinent medical history including labs and information for this member that may support approval.**  
**Please answer the following questions and sign.**

Q1. Does the patient have a confirmed diagnosis of pseudobulbar affect (PBA)?

☐ Yes

☐ No

Q2. Is the patient 18 years of age or older?

☐ Yes

☐ No

Q3. Is the requested drug being prescribed by or in consultation with a neurologist?

☐ Yes

☐ No

Q4. Does the patient have a history of quinidine, quinine, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions?

☐ Yes

☐ No

Q5. Will the requested drug be used with a monoamine oxidase inhibitor (MAOI) or within 14 days after stopping a MAOI?

☐ Yes

☐ No



**MEDICARE ADVANTAGE  
PRIOR AUTHORIZATION REQUEST FORM**

Nuedexta - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Member Name:</b>	<b>Prescriber Name:</b>
<p>Q6. Does the patient have a history of prolonged QT interval, congenital long QT syndrome, torsades de pointes, heart failure, or complete atrioventricular (AV) block without implanted pacemaker?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q7. Will the requested drug be used concomitantly with quinidine, quinine, mefloquine, or drugs that both prolong the QT interval and are metabolized by CYP2D6 (e.g., thioridazine or pimozide)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q8. Is the patient at risk for QT prolongation and torsades de pointes? includes patients concomitantly taking medications that prolong the QT interval and patients with left ventricular hypertrophy or left ventricular dysfunction.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q9. Will the patient have a baseline EKG and an EKG evaluation 3 to 4 hours after the first dose?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q10. Requested Duration:</p> <p><input type="checkbox"/> 12 Months <input type="checkbox"/> Other</p>	
<p>Q11. Additional Information:</p>	

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

v2026